NCT00374140 - Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2012

Conditions

Small Cell Lung Cancer

Interventions

DRUG

RAD001 (everolimus)

10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities

Trial Locations (19)

15009

UPMC Cancer Center - Beaver, Beaver

15025

UPMC Cancer Center - Clairton, Clairton

15090

UPMC Cancer Center - North Hills, Wexford

15108

UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group, Moon Township

15132

UPMC Cancer Center - McKeesport, McKeesport

15146

UPMC Cancer Center - Monroeville, Monroeville

15215

UPMC Cancer Center - St. Margaret's, Pittsburgh

15219

UPMC Cancer Center - Mercy, Pittsburgh

15232

University of Pittsburgh Cancer Institute - Hillman Cancer Center, Pittsburgh

15237

UPMC Cancer Center - Passavant, Pittsburgh

15241

UPMC Cancer Center - Upper St. Clair, Pittsburgh

15301

UPMC Cancer Center - Washington, Washington

15401

UPMC Cancer Center - Uniontown, Uniontown

15601

UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg, Greensburg

UPMC Cancer Center - Oakbrook Commons - Greensburg, Greensburg

15701

UPMC Cancer Center - Indiana, Indiana

15901

UPMC Cancer Center - John P. Murtha Pavilion - Johnstown, Johnstown

16105

UPMC Cancer Center - New Castle, New Castle

43952

UPMC Cancer Center - Teramana Cancer Center - Steubenville, Steubenville